{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:35:52Z","timestamp":1760297752629},"reference-count":79,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2007,2,1]],"date-time":"2007-02-01T00:00:00Z","timestamp":1170288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2007,2]]},"DOI":"10.1016\/j.ijantimicag.2006.09.018","type":"journal-article","created":{"date-parts":[[2007,1,5]],"date-time":"2007-01-05T13:58:59Z","timestamp":1168005539000},"page":"136-143","source":"Crossref","is-referenced-by-count":23,"title":["Caspofungin for the treatment of fungal infections: a systematic review of randomized controlled trials"],"prefix":"10.1016","volume":"29","author":[{"given":"Matthew E.","family":"Falagas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fotinie","family":"Ntziora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregoria I.","family":"Betsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Samonis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2006.09.018_bib1","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.arcmed.2005.05.015","article-title":"Invasive candidiasis in immunocompromised hospitalized patients","volume":"36","author":"Sims","year":"2005","journal-title":"Arch Med Res"},{"key":"10.1016\/j.ijantimicag.2006.09.018_bib2","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1128\/JCM.43.9.4902-4904.2005","article-title":"Breakthrough disseminated Aspergillus ustus infection in allogeneic hematopoietic stem cell transplant recipients receiving voriconazole or caspofungin prophylaxis","volume":"43","author":"Pavie","year":"2005","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2006.09.018_bib3","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.diagmicrobio.2005.04.009","article-title":"Nonfatal pulmonary Trichoderma viride infection in an adult patient with acute myeloid leukemia: report of one case and review of the literature","volume":"53","author":"De Miguel","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2006.09.018_bib4","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1055\/s-2005-868738","article-title":"Update on therapy of invasive mycoses in hematology and oncology","volume":"130","author":"Maschmeyer","year":"2005","journal-title":"Dtsch Med Wochenschr"},{"key":"10.1016\/j.ijantimicag.2006.09.018_bib5","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s10096-005-1327-5","article-title":"A case of Aspergillus mediastinitis after heart transplantation successfully treated with liposomal amphotericin B, caspofungin and voriconazole","volume":"24","author":"Forestier","year":"2005","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2006.09.018_bib6","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s15010-005-4070-z","article-title":"Systemic aspergillosis with predominant genitourinary manifestations in an immunocompetent man: what we can learn from a disastrous follow-up","volume":"33","author":"Ludwig","year":"2005","journal-title":"Infection"},{"issue":"Suppl. 1","key":"10.1016\/j.ijantimicag.2006.09.018_bib7","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1093\/ajhp\/62.suppl_1.S17","article-title":"Overview of transplant mycology","volume":"62","author":"Golan","year":"2005","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.ijantimicag.2006.09.018_bib8","first-page":"5","article-title":"Management of invasive mycoses in hematology patients: current approaches","volume":"18","author":"Perfect","year":"2004","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.ijantimicag.2006.09.018_bib9","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/sj.bmt.1704603","article-title":"Choices aplenty: antifungal prophylaxis in hematopoietic stem cell transplant recipients","volume":"34","author":"Hamza","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.ijantimicag.2006.09.018_bib10","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0163-4453(03)00134-8","article-title":"Fatal Scopulariopsis brevicaulis infection in a paediatric stem-cell transplant patient treated with voriconazole and caspofungin and a review of Scopulariopsis infections in immunocompromised patients","volume":"48","author":"Steinbach","year":"2004","journal-title":"J Infect"},{"key":"10.1016\/j.ijantimicag.2006.09.018_bib11","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1053\/srin.2002.33443","article-title":"Invasive Aspergillus infections in hematologic malignancy patients","volume":"17","author":"Perea","year":"2002","journal-title":"Semin Respir Infect"},{"key":"10.1016\/j.ijantimicag.2006.09.018_bib12","first-page":"227","article-title":"Management of mycoses in patients with hematologic disease and cancer, review of the literature","volume":"7","author":"Ruhnke","year":"2002","journal-title":"Eur J Med Res"},{"key":"10.1016\/j.ijantimicag.2006.09.018_bib13","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/jac\/49.2.239","article-title":"New antifungal agents\u2014treatment standards are beginning to grow old","volume":"49","author":"Maschmeyer","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2006.09.018_bib14","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/cncr.21615","article-title":"Efficacy of caspofungin against invasive Candida or invasive Aspergillus infections in neutropenic patients","volume":"106","author":"Betts","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.ijantimicag.2006.09.018_bib15","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2174\/1568005054880145","article-title":"Combination antifungal therapy for invasive aspergillosis: utilizing new targeting strategies","volume":"5","author":"Steinbach","year":"2005","journal-title":"Curr Drug Targets Infect Disord"},{"key":"10.1016\/j.ijantimicag.2006.09.018_bib16","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.2165\/00003495-200565140-00009","article-title":"Caspofungin: a review of its use in the treatment of fungal infections","volume":"65","author":"McCormack","year":"2005","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2006.09.018_bib17","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.clinthera.2005.06.010","article-title":"Anidulafungin: a new echinocandin with a novel profile","volume":"27","author":"Vazquez","year":"2005","journal-title":"Clin Ther"},{"key":"10.1016\/j.ijantimicag.2006.09.018_bib18","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1439-0507.2005.01131.x","article-title":"Pharmacological properties and clinical efficacy of a recently licensed systemic antifungal, caspofungin","volume":"48","author":"Maschmeyer","year":"2005","journal-title":"Mycoses"},{"key":"10.1016\/j.ijantimicag.2006.09.018_bib19","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1159\/000084627","article-title":"Antifungal chemotherapeutics","volume":"14","author":"Krcmery","year":"2005","journal-title":"Med Princ Pract"},{"key":"10.1016\/j.ijantimicag.2006.09.018_bib20","first-page":"15","article-title":"Antifungal resistance: the clinical front","volume":"18","author":"Perfect","year":"2004","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.ijantimicag.2006.09.018_bib21","first-page":"24","article-title":"Combination antifungal therapy: where are we now, and where are we going?","volume":"18","author":"Marr","year":"2004","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.ijantimicag.2006.09.018_bib22","first-page":"15","article-title":"Use of newer antifungal therapies in clinical practice: what do the data tell us?","volume":"18","author":"Perfect","year":"2004","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.ijantimicag.2006.09.018_bib23","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/00001432-200412000-00002","article-title":"Impact of real-time fungal susceptibility on clinical practices","volume":"17","author":"Magiorakos","year":"2004","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2006.09.018_bib24","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s10096-004-1228-z","article-title":"Pharmacokinetics\/pharmacodynamics of echinocandins","volume":"23","author":"Theuretzbacher","year":"2004","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2006.09.018_bib25","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1586\/14787210.2.2.253","article-title":"Recent advances in antifungal pharmacotherapy for invasive fungal infections","volume":"2","author":"Gallagher","year":"2004","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.ijantimicag.2006.09.018_bib26","first-page":"121","article-title":"In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature","volume":"20","author":"Espinel-Ingroff","year":"2003","journal-title":"Rev Iberoam Micol"},{"key":"10.1016\/j.ijantimicag.2006.09.018_bib27","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.2165\/00003495-200464180-00001","article-title":"Newer systemic antifungal agents: pharmacokinetics, safety and efficacy","volume":"64","author":"Boucher","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2006.09.018_bib28","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.2165\/00003495-200464110-00002","article-title":"Mucosal and systemic fungal infections in patients with AIDS: prophylaxis and treatment","volume":"64","author":"Ruhnke","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2006.09.018_bib29","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1053\/j.seminoncol.2004.02.020","article-title":"New options for the treatment of invasive fungal infections","volume":"31","author":"Rubin","year":"2004","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ijantimicag.2006.09.018_bib30","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/BF02724279","article-title":"Newer antifungal agents","volume":"71","author":"Abuhammour","year":"2004","journal-title":"Indian J Pediatr"},{"key":"10.1016\/j.ijantimicag.2006.09.018_bib31","first-page":"8","article-title":"CNS-aspergillosis: are there new treatment options?","volume":"46","author":"Schwartz","year":"2003","journal-title":"Mycoses"},{"key":"10.1016\/j.ijantimicag.2006.09.018_bib32","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1517\/14712598.4.2.233","article-title":"Genetically recombinant antibodies: new therapeutics against candidiasis","volume":"4","author":"Burnie","year":"2004","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.ijantimicag.2006.09.018_bib33","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.bbmt.2003.09.014","article-title":"A new era of antifungal therapy","volume":"10","author":"Wingard","year":"2004","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.ijantimicag.2006.09.018_bib34","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1592\/phco.23.14.1441.31938","article-title":"Systemic antifungal therapy: new options, new challenges","volume":"23","author":"Wong-Beringer","year":"2003","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2006.09.018_bib35","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/S0140-6736(03)14472-8","article-title":"Echinocandin antifungal drugs","volume":"362","author":"Denning","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2006.09.018_bib36","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.2165\/00003495-200363200-00008","article-title":"Caspofungin: a review of its use in oesophageal candidiasis, invasive candidiasis and invasive aspergillosis","volume":"63","author":"Keating","year":"2003","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2006.09.018_bib37","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S1368-7646(03)00064-5","article-title":"Caspofungin: the first in a new class of antifungal agents","volume":"6","author":"Kartsonis","year":"2003","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.ijantimicag.2006.09.018_bib38","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1517\/13543784.12.8.1313","article-title":"The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy","volume":"12","author":"Wiederhold","year":"2003","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.ijantimicag.2006.09.018_bib39","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/00001622-200307000-00001","article-title":"New antifungal drugs and new clinical trials: interpreting results may be difficult","volume":"15","author":"Girmenia","year":"2003","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.ijantimicag.2006.09.018_bib40","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1185\/030079903125001884","article-title":"Review of the safety, tolerability, and drug interactions of the new antifungal agents caspofungin and voriconazole","volume":"19","author":"Ullmann","year":"2003","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.ijantimicag.2006.09.018_bib41","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1097\/00001432-200212000-00004","article-title":"Laboratory evaluation of new antifungal agents against rare and refractory mycoses","volume":"15","author":"Sutton","year":"2002","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2006.09.018_bib42","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1517\/14656566.4.5.807","article-title":"Caspofungin: first approved agent in a new class of antifungals","volume":"4","author":"Johnson","year":"2003","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.ijantimicag.2006.09.018_bib43","doi-asserted-by":"crossref","first-page":"971","DOI":"10.2165\/00003495-200363100-00004","article-title":"Invasive oesophageal candidiasis: current and developing treatment options","volume":"63","author":"Vazquez","year":"2003","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2006.09.018_bib44","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1439-0507.2002.tb04771.x","article-title":"The first echinocandin: caspofungin","volume":"45","author":"Cornely","year":"2002","journal-title":"Mycoses"},{"key":"10.1016\/j.ijantimicag.2006.09.018_bib45","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1093\/jac\/dkg117","article-title":"Caspofungin: the first representative of a new antifungal class","volume":"51","author":"Letscher-Bru","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2006.09.018_bib46","doi-asserted-by":"crossref","unstructured":"Polak A. Antifungal therapy\u2014state of the art at the beginning of the 21st century. Prog Drug Res 2003;Spec No:59\u2013190.","DOI":"10.1007\/978-3-0348-7974-3_4"},{"key":"10.1016\/j.ijantimicag.2006.09.018_bib47","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1358\/dot.2002.38.12.820101","article-title":"Caspofungin","volume":"38","author":"Chandrasekar","year":"2002","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.ijantimicag.2006.09.018_bib48","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1345\/aph.1C114","article-title":"Caspofungin acetate for treatment of invasive fungal infections","volume":"37","author":"Pacetti","year":"2003","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ijantimicag.2006.09.018_bib49","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1034\/j.1399-3062.2002.01004.x","article-title":"Safety and tolerability of caspofungin acetate in the treatment of fungal infections","volume":"4","author":"Sable","year":"2002","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.ijantimicag.2006.09.018_bib50","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1097\/00001432-200112000-00004","article-title":"Clinical efficacy of echinocandin antifungals","volume":"14","author":"Arathoon","year":"2001","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2006.09.018_bib51","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0149-2918(02)85039-1","article-title":"Caspofungin: an echinocandin antifungal agent","volume":"24","author":"Stone","year":"2002","journal-title":"Clin Ther"},{"key":"10.1016\/j.ijantimicag.2006.09.018_bib52","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1517\/13543784.10.8.1545","article-title":"Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections","volume":"10","author":"Groll","year":"2001","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.ijantimicag.2006.09.018_bib53","first-page":"468","article-title":"Hitting a new target with echinocandins. Why chase something else?","volume":"2","author":"Graybill","year":"2001","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1016\/j.ijantimicag.2006.09.018_bib54","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1093\/ajhp\/58.13.1206","article-title":"Caspofungin acetate: an antifungal agent","volume":"58","author":"Hoang","year":"2001","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.ijantimicag.2006.09.018_bib55","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1517\/13543784.10.2.269","article-title":"Update on antifungals targeted to the cell wall: focus on beta-1,3-glucan synthase inhibitors","volume":"10","author":"Georgopapadakou","year":"2001","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.ijantimicag.2006.09.018_bib56","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.jinf.2005.01.016","article-title":"Invasive candidiasis in cancer patients: observations from a randomized clinical trial","volume":"50","author":"DiNubile","year":"2005","journal-title":"J Infect"},{"key":"10.1016\/j.ijantimicag.2006.09.018_bib57","doi-asserted-by":"crossref","first-page":"4306","DOI":"10.1128\/AAC.48.11.4306-4314.2004","article-title":"Potential for interactions between caspofungin and nelfinavir or rifampin","volume":"48","author":"Stone","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2006.09.018_bib58","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1056\/NEJMoa040446","article-title":"Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia","volume":"351","author":"Walsh","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2006.09.018_bib59","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1007\/s10096-003-0973-8","article-title":"Global distribution and outcomes for Candida species causing invasive candidiasis: results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis","volume":"22","author":"Colombo","year":"2003","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2006.09.018_bib60","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1128\/AAC.46.2.451-457.2002","article-title":"Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases","volume":"46","author":"Arathoon","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2006.09.018_bib61","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa021585","article-title":"Caspofungin invasive candidiasis study group. Comparison of caspofungin and amphotericin B for invasive candidiasis","volume":"347","author":"Mora-Duarte","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2006.09.018_bib62","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S0002-9343(02)01191-9","article-title":"A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis","volume":"113","author":"Villanueva","year":"2002","journal-title":"Am J Med"},{"key":"10.1016\/j.ijantimicag.2006.09.018_bib63","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1089\/088922202760265579","article-title":"Response and relapse rates of candidal esophagitis in HIV-infected patients treated with caspofungin","volume":"18","author":"Dinubile","year":"2002","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.ijantimicag.2006.09.018_bib64","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1128\/AAC.46.3.739-745.2002","article-title":"Single- and multiple-dose pharmacokinetics of caspofungin in healthy men","volume":"46","author":"Stone","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2006.09.018_bib65","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1086\/323401","article-title":"A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis","volume":"33","author":"Villanueva","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2006.09.018_bib66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.ijantimicag.2006.09.018_bib67","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/cncr.21615","article-title":"Efficacy of caspofungin against invasive Candida or invasive Aspergillus infections in neutropenic patients","volume":"106","author":"Betts","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.ijantimicag.2006.09.018_bib68","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1128\/AAC.44.9.2310-2318.2000","article-title":"Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice","volume":"44","author":"Abruzzo","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2006.09.018_bib69","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1128\/AAC.41.11.2333","article-title":"Evaluation of the echinocandin antifungal MK-0991 (L-743, 872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis","volume":"41","author":"Abruzzo","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2006.09.018_bib70","doi-asserted-by":"crossref","first-page":"4911","DOI":"10.1128\/AAC.48.12.4911-4914.2004","article-title":"Need for early antifungal treatment confirmed in experimental disseminated Candida albicans infection","volume":"48","author":"MacCallum","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2006.09.018_bib71","doi-asserted-by":"crossref","first-page":"3634","DOI":"10.1128\/AAC.46.11.3634-3636.2002","article-title":"In vitro pharmacodynamic properties of three antifungal agents against preformed Candida albicans biofilms determined by time\u2013kill studies","volume":"46","author":"Ramage","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2006.09.018_bib72","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1128\/AAC.47.10.3149-3154.2003","article-title":"Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States","volume":"47","author":"Ostrosky-Zeichner","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2006.09.018_bib73","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.diagmicrobio.2005.03.002","article-title":"Antifungal susceptibility of Candida spp. isolated from pediatric patients: a survey of 4 children's hospitals","volume":"52","author":"Zaoutis","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2006.09.018_bib74","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1093\/jac\/dkh548","article-title":"In vitro susceptibilities of bloodstream isolates of Candida species to six antifungal agents: results from a population-based active surveillance programme, Barcelona, Spain, 2002\u20132003","volume":"55","author":"Cuerca-Estella","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2006.09.018_bib75","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1080\/13693780410001731565","article-title":"In vitro activity of caspofungin compared to amphotericin B, fluconazole, and itraconazole against Candida strains isolated in a Turkish University Hospital","volume":"43","author":"Arikan","year":"2005","journal-title":"Med Mycol"},{"key":"10.1016\/j.ijantimicag.2006.09.018_bib76","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1128\/AAC.46.5.1240-1245.2002","article-title":"Efficacies of fluconazole, caspofungin, and amphotericin B in Candida glabrata-infected p47phox\u2212\/\u2212 knockout mice","volume":"46","author":"Ju","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2006.09.018_bib77","doi-asserted-by":"crossref","first-page":"4989","DOI":"10.1128\/AAC.49.12.4989-4992.2005","article-title":"Comparison of the fungicidal activities of caspofungin and amphotericin B against Candida glabrata","volume":"49","author":"Barchiesi","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2006.09.018_bib78","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1093\/ndt\/gfh948","article-title":"Caspofungin is less nephrotoxic than amphotericin B in vitro and predominantly damages distal renal tubular cells","volume":"20","author":"Wegner","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ijantimicag.2006.09.018_bib79","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.2165\/00003495-200363200-00008","article-title":"Caspofungin: a review of its use in oesophageal candidiasis, invasive candidiasis and invasive aspergillosis","volume":"63","author":"Keating","year":"2003","journal-title":"Drugs"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092485790600433X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092485790600433X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,23]],"date-time":"2019-04-23T14:25:31Z","timestamp":1556029531000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092485790600433X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2]]},"references-count":79,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,2]]}},"alternative-id":["S092485790600433X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2006.09.018","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2007,2]]}}}